About Seqirus
Seqirus is a company based in Maidenhead (United Kingdom) founded in 1916.. The company has 29,000 employees as of June 30, 2025. Seqirus operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Serum Institute of India, Vaxcyte and Generate Biomedicines, among others.
- Headquarter Maidenhead, United Kingdom
- Employees 29000 as on 30 Jun, 2025
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Csl Limited
-
Annual Revenue
$15.56 B (USD)6.28as on Jun 30, 2025
-
Net Profit
$3.03 B (USD)14.97as on Jun 30, 2025
-
EBITDA
$5.09 B (USD)10.08as on Jun 30, 2025
-
Latest Funding Round
-
Investors
-
Employee Count
29000
as on Jun 30, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Seqirus
Seqirus is a publicly listed company on the ASX with ticker symbol CSL in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Seqirus
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Seqirus
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Seqirus
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Seqirus Comparisons
Competitors of Seqirus
Seqirus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Serum Institute of India, Vaxcyte and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Seqirus
Frequently Asked Questions about Seqirus
When was Seqirus founded?
Seqirus was founded in 1916.
Where is Seqirus located?
Seqirus is headquartered in Maidenhead, United Kingdom.
How many employees does Seqirus have?
As of Jun 30, 2025, the latest employee count at Seqirus is 29,000.
What is the annual revenue of Seqirus?
Annual revenue of Seqirus is $15.56B as on Jun 30, 2025.
What does Seqirus do?
Seqirus was founded in 1916 and is headquartered in Maidenhead, United Kingdom. Operations focus on the pharmaceutical sector, specifically the development of influenza vaccines. Inactivated quadrivalent vaccines like Afluria Quadrivalent and Afluria are produced, alongside others such as Agrippal, Fluad, and Flucelvax. These products are distributed globally for seasonal and pandemic influenza prevention, supporting public health initiatives in various regions.
Who are the top competitors of Seqirus?
Seqirus's top competitors include Moderna, Adaptive Biotechnologies and Vaxcyte.
Is Seqirus publicly traded?
Yes, Seqirus is publicly traded on ASX under the ticker symbol CSL.
What is Seqirus's ticker symbol?
The ticker symbol of Seqirus is CSL on ASX.